Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Core Insights - Sarepta Therapeutics, Inc. is a leader in precision genetic medicine for rare diseases and has reported preliminary financial results for Q4 and full-year 2025 [1] Financial Update - The company presented its preliminary and unaudited total net product revenues as part of its participation in the 44th Annual J.P. Morgan Healthcare Conference [1] - As of December 31, 2025, Sarepta reported cash, cash equivalents, restricted cash, and investments on hand [1]